PDB21 Natural History of Beta Cell Rate of Decline and Its Effect on Development of Secondary Complications in Type 1 Diabetes

Abstract

tically significant for both feet (pϽ0.001). Hyperkeratosis of both feet, evaluated by the doctor, significantly improves after 4 weeks of treatment. The efficacy score measured by the patient is 16.4 (Ϯ 4.8) on inclusion. Measured under the same conditions, it is 7.7 (Ϯ 3.2) at 4 weeks. The difference is statistically significant (pϽ0.001). Treatment compliance is good since 89% confirm that they respected the dosage, a trend confirmed by the fact that 94% of subjects say that they are satisfied with the product. CONCLUSIONS: By means of a validated score (XAS) and a patient evaluation scale, the efficacy of Pedimed in treating the diabetic foot is confirmed.